---
schema_version: "secwatch.filing_event.v1"
accession: "0001619856-22-000036"
form_type: "8-K"
ticker: "CRBU"
cik: "0001619856"
company_name: "Caribou Biosciences, Inc."
filed_at: "2022-12-12T23:59:59+00:00"
generated_at: "2026-06-21T06:10:28.059838+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Caribou: 12-month CB-010 data shows durable CR in 2/6; selects ROR1 for CB-020

## Summary
- CB-010 ANTLER cohort 1: 6/6 CR best response; 3/6 durable CR at 6 months; 2/6 maintain CR at 12 months; longest CR 18 months.
- FDA granted CB-010 RMAT and Fast Track designations; dose level 2 (80x10^6) no DLTs; enrolling dose level 3 (120x10^6).
- Selected ROR1 as target for CB-020 iPSC-derived allogeneic CAR-NK cell therapy; preclinical data shows significant tumor burden reduction in xenograft model.
- Armoring strategies for CAR-NK platform: CBLB knockout, B2M knockout with HLA-E insertion, membrane-bound IL-15/IL-15RA fusion.

## SEC filing metadata
- accession: 0001619856-22-000036
- form_type: 8-K
- ticker: CRBU
- cik: 0001619856
- company_name: Caribou Biosciences, Inc.
- filed_at: 2022-12-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1619856/000161985622000036/0001619856-22-000036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1619856/000161985622000036/crbu-20221212.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001619856-22-000036
- JSON: https://secwatch.observer/filing/0001619856-22-000036.json
- Plain text: https://secwatch.observer/filing/0001619856-22-000036.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.